David Liew drdavidliew
1 year 3 months ago
LEVI-04 (neutrophin-3 inhibitor presented as #ACR24 late-breaker in knee OA)
more good efficacy data, no rapidly progressive OA safety signal.
For us clinicians: impressive impact size, esp relative to alternatives.
Finally, something that works??
#EULAR2025 OP0374 @RheumNow https://t.co/iVdlwyaqrv
David Liew drdavidliew
1 year 3 months ago
It’s a hot topic at #EULAR2025, but the messages on AI in medicine from patient-professional discussions is clear:
- potential upside massive in many domains, but
- patients still want their clinicians by their side
#EULAR2025 meeting highlights @RheumNow https://t.co/4T6gE7TeQp
Antoni Chan MD (Prof) synovialjoints
1 year 3 months ago
Great talk by @Lupusreference on Relapsing Polychondritis and a highlight of #EULAR2025. Do not forget about the articular presentations of relapsing polychondritis @RheumNow https://t.co/1xZY7VkX1z
Gout flares are associated with cardiovascular events. Treating gout to target serum urate level prevents flares, but whether such treatment can also prevent cardiovascular events is unknown.
Dr. John Cush RheumNow
1 year 3 months ago
EULAR Classification criteria for hemachromatosis, presented by Prof. Kiely shows clinical pearls in diagnosis - Hook osteophytes @MCP 2/3, & Iron Fist sign w/ elevation of MCPs 2&3. #EULAR2025 https://t.co/S8iA0C4pwG
Dr. John Cush RheumNow
1 year 3 months ago
EULAR 2025 - Day 1 Report
Wednesday was Day One at EULAR 2025 in Barcelona. Thousands from around the world gathered, eager to reunite at this international educational forum. Below are a few of my favorites from Day 1.
https://t.co/ycQT2dfVXe https://t.co/Qa58ofW411
Dr. John Cush RheumNow
1 year 3 months ago
Health Literacy Matters in Rheumatic Disease Care
Dr. Mrinalini Dey reports on abstract OP0026, "Health literacy associates with clinical, treatment and work status in people with inflammatory arthritis: Results from a national cohort", presented at EULAR 2025 in Barcelona, https://t.co/f45rxHBYnY
Highlights from today included presentations on imaging in vasculitis, a debate on whether to treat high risk pre-clinical RA, and EULAR Recommendations on a) Treatment of interstitial lung disease (ILD); b) Physical Activity in people with arthritis; and c) EULAR disease activity score for antiphospholipid syndrome and d) the management of SLE nephritis. Below are a few others that caught my eye today.
Adela Castro AdelaCastro222
1 year 3 months ago
NMA of 14RCTs (>2500 pts) eval relative efficacy of bDMARDs and tsDMARDs in mostly biologic naïve nr-axSpA pts.
-All therapies studied significantly improved ASAS40 response rates compared to placebo.
-Certolizumab and Golimumab were the most effective therapies, followed by https://t.co/BJLRpEDYrv
Adela Castro AdelaCastro222
1 year 3 months ago
👁️Uveitis in axSpA:
-Up to 40% can present before SpA dx
-NMA of 44 RCTs showed tx with TNFi, JAKi and IL-17i protective effects against uveitis
-Low rates of uveitis in axSpA pts on BIME trials suggests its possible beneficial effects.
#EULAR2025
@RheumNow https://t.co/mPuSMnD1Zs
Antoni Chan MD (Prof) synovialjoints
1 year 3 months ago
In 30 axSpA pts (mean age 42 yrs, BASDAI 3.5, BASFI 2.8, BASMI 2.0, chest expansion 4.5 cm), an 8-wk individualized exercise (cardiorespiratory + trunk strength via cardiopulmonary exercise testing [CPET] & David Back Concept [DBC] devices) ↓ trunk strength deficit 14.1% & https://t.co/505cCEOzu1
